Saphnelo® (anifrolumab-fnia) – New drug approval
August 2, 2021 - AstraZeneca announced the FDA approval of Saphnelo (anifrolumab-fnia), for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
Download PDF
